“Doubling time” of PSA is a significant prognostic factor in recurrence.
In this video Benjamin Miron, MD, a medical oncologist at Fox Chase Cancer Center, discusses the diagnosis and treatment of patients with intraductal carcinoma of the prostate.
Don’t forget about the rest of your body!
In this video, Brian F. Chapin, MD, discusses the FDA approval of flotufolastat F 18 (Posluma) will improve the care of patients with prostate cancer.
A new study suggests that following such a diet after diagnosis may also improve patients’ quality of life.
Catching cancer cells in the blood